| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_69ece09bafee7e0c49d1f7951a3faa2c |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K16-28 |
| filingDate |
2007-12-21-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_20678323b136694c3d78d0a41438e791
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_88d471aa80101e796e1aae2a8853ee4c |
| publicationDate |
2009-12-30-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
CN-101616934-A |
| titleOfInvention |
Suppress DR6 antibody and the purposes in treatment neuroscience illness thereof of DR6 in conjunction with APP |
| abstract |
The method and composition that comprises the DR6 antagonist that is used for the treatment of neuroscience illness (comprising Alzheimer's) is provided.The DR6 antagonist comprises anti-APP antibody, anti-DR6 antibody, DR6 immunoadhesin and the DR6 variant (and fusion rotein) of the growth, regeneration or the survival that strengthen mammalian nervous unit cell or tissue. |
| isCitedBy |
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/CN-103492415-B
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/CN-103492415-A
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/CN-102770767-A
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/CN-107690279-B
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/CN-113811330-A
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/CN-107690279-A |
| priorityDate |
2006-12-22-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |